Boehringer begins Phase 3 survodutide trial in type 2 diabetes
The three-part placebo-controlled study enrolls adults with type 2 diabetes and BMI of at least 23.
PR
By Priya Raman · Science Reporter
Sep 17 08:00 ETSource: ClinicalTrials.gov
The wire
- 01Boehringer Ingelheim is recruiting for a Phase 3 trial of survodutide for blood sugar control in type 2 diabetes.
- 02Expands the glucagon/GLP-1 dual agonist beyond obesity indications.
- 03Readout timing and endpoints details not specified.
From the source
Read at clinicaltrials.govA Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
NCT07754461 · PHASE3 · RECRUITING · Sponsor: Boehringer Ingelheim · Conditions: Type 2 Diabetes. This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join. The study has 3 parts. In each part the study compares survodutide with placebo. Survodutide is being developed to treat several health problems including type 2 diabetes. Placebo looks
Source URL https://clinicaltrials.gov/study/NCT07754461